Search
Zymeworks Inc
ZYMEAdd to Watchlist
25.720USD
-0.420-1.61%
Close 07/01, 16:00（ET）Quotes delayed by 15 min
1.93BMarket Cap
LossP/E TTM
View Detailed Chart
TradingKey 图表Intraday
1m
30m
1h
D
W
M
D
Today
-1.61%
5 Days
+5.84%
1 Month
+4.81%
6 Months
-2.32%
Year to Date
-2.32%
1 Year
+107.25%
Key Figures
26.140Open
26.385High
558.63KVolume
LossP/E TTM
25.65P/E Dynamic
--Dividend TTM
0.74%Turnover Ratio
26.140Prev. Close
25.300Low
9.77MTurnover
LossP/E Static
7.20P/B
0.00%Div Yield TTM
-22.72%ROA
29.75052wk High
0.70Volume Ratio
-122.69MNet Profit
75.19MShares
-1.3662EPS TTM
1.16Beta
-42.02%ROE
11.02052wk Low
4.15%Amplitude
100.00%Gross Margin
1.93BMarket Cap
3.26Reward/Risk
2.58%Risk Rate
TradingKey Stock Score of Zymeworks Inc
Currency: USD Updated: 2026-07-01Key Insights
Zymeworks Inc's fundamentals are relatively healthy, and its growth potential is significant.Its valuation is considered fairly valued, ranking 40 out of 387 in the Biotechnology & Medical Research industry.Institutional ownership is very high.Over the past month, multiple analysts have rated it as Buy, with the highest price target at 39.08.In the medium term, the stock price is expected to remain stable.Despite a good stock market performance and strong technicals over the past month, the fundamentals don't support the current trend.The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
Zymeworks Inc's Score
Support & Resistance
Relevant data have not been disclosed by the company yet.
Score Analysis
Current score
Previous score
Media Coverage
Last 24 hours
Coverage Level
Very Low
Very High
Positive
Zymeworks Inc Highlights
StrengthsRisks
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
High Growth
The company's revenue has grown steadily over the past 3 years, averaging 39.41% year-on-year.
Undervalued
The company’s latest PE is -18.83, at a low 3-year percentile range.
Held by Chuck Royce
Star Investor Chuck Royce holds 302.14K shares of this stock.
Analyst Rating
Based on
12
analysts
Buy
Current Rating
39.083
Target Price
+49.52%
Upside Space
Zymeworks Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
Relevant data have not been disclosed by the company yet.
Total revenue
Relevant data have not been disclosed by the company yet.
Zymeworks Inc Info
Zymeworks Inc. is a global clinical-stage biotechnology company. The Company is developing a diverse pipeline of multifunctional biotherapeutics to improve the standard of care for difficult-to-treat diseases such as cancer, autoimmune and inflammatory diseases (AIID). The Company engineered and developed zanidatamab, a HER2-targeted bispecific antibody using the Company’s Azymetric technology. It has entered into separate agreements with BeiGene, Ltd. and Jazz Pharmaceuticals Ireland Limited, granting each exclusive rights to develop and commercialize zanidatamab in different territories. It is advancing a pipeline of wholly-owned product candidates, leveraging its expertise in both antibody-drug conjugates and multispecific antibody therapeutics targeting novel pathways in areas of significant unmet medical need. The Company has two clinical-stage product candidates: ZW171 and ZW191. Its preclinical product candidates include ZW251, ZW220, ZW209, and ZW1528.
Ticker SymbolZYME
CompanyZymeworks Inc
CEOGalbraith (Kenneth H)
Websitehttps://www.zymeworks.com/
Related Instruments
-0.64%
-0.05%
-2.95%
-0.23%
-2.41%
-1.64%
-0.22%
+1.75%
-0.29%
-0.79%
+0.26%
-2.00%
-2.10%
-2.41%
+1.68%
0.00%
+0.19%
-1.97%
+0.06%
-0.44%Popular Instruments
52358.200
+103.900 (+0.20%)
29957.400
+158.100 (+0.53%)
7499.800
+24.300 (+0.33%)
14988.000
-367.000 (-2.39%)
69819.000
+334.000 (+0.48%)
6298.200
+22.800 (+0.36%)
67.661
-0.307 (-0.45%)
294.380
+5.020 (+1.73%)
197.580
-2.510 (-1.25%)
4055.170
+24.400 (+0.60%)
FAQs
What is the current price of Zymeworks Inc (ZYME)?
The current price of Zymeworks Inc (ZYME) is 25.72.
What is the symbol of Zymeworks Inc?
The ticker symbol of Zymeworks Inc is ZYME.
What is the 52-week high of Zymeworks Inc?
The 52-week high of Zymeworks Inc is 29.75.
What is the 52-week low of Zymeworks Inc?
The 52-week low of Zymeworks Inc is 11.02.
What is the market capitalization of Zymeworks Inc?
The market capitalization of Zymeworks Inc is 1.93B.
Is Zymeworks Inc (ZYME) currently rated as Buy, Hold, or Sell?
According to analysts, Zymeworks Inc (ZYME) has an overall rating of Buy, with a price target of 39.08.
What is the Earnings Per Share (EPS TTM) of Zymeworks Inc (ZYME)?
The Earnings Per Share (EPS TTM) of Zymeworks Inc (ZYME) is -1.08.